-

Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a more than $200 million endowment to the Gilead Foundation to further the company's vision of creating a healthier world for all people. The Gilead Foundation, established in 2005, builds on the company’s longstanding commitment to supporting underserved communities around the world. It aims to create impact in the community and society by encouraging a culture of giving, engaging in local communities and exploring innovative approaches to complex social issues.

“Giving back to charitable organizations in the communities in which we live and work has helped define Gilead as a company,” said Keeley Wettan, Senior Vice President, Legal, Gilead Sciences and Gilead Foundation Board Chair. “Gilead’s employees work hard every day to bring new possibilities to millions of people around the world, and we are proud that the Gilead Foundation will be able to create new possibilities for organizations that are doing the same.”

The Gilead Foundation has three core programs: the Creating Possible Fund, charitable donations to local community organizations and the donation matching program for employees.

A new pillar of the Gilead Foundation is the Creating Possible Fund, which will award grants to organizations that aim to build a more just society with a focus on health justice. Funding will support innovative approaches to complex social issues, especially those affecting the most underserved members of society, including people of color and LGBTQ+ youth. Additional details about the fund, including information on how to apply, will be announced later this year.

The charitable donations program contributes to local communities where Gilead employees live and work, with an emphasis on programs that support social service programs, including responding to disaster and humanitarian relief efforts. Similar to Gilead’s other philanthropic efforts, the Gilead Foundation will partner with internal and external stakeholders to inform programmatic priorities and strategies. The application process for these grants also will be announced later this year.

The donation matching program for employees, Giving Together, will increase the annual match for donations made by Gilead employees to eligible nonprofit organizations to $15,000. A special campaign will match donations to Room to Read, The NEA Foundation and the Oakland Public Education Fund’s #OaklandUndivided campaign during the month of August.

The Gilead Foundation programs broaden the philanthropic reach of the company, whose giving focuses on improving access to healthcare, reducing health barriers for underserved populations and advancing disease education in Gilead’s therapeutic areas of focus. In 2020, Gilead provided $409 million globally in cash donations to organizations addressing community need in areas such as COVID-19, co-pay assistance, racial equity, wildfire relief and LGBTQ+ support.

For more information on the Gilead Foundation, visit: https://www.gilead.com/purpose/giving/gilead-foundation.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead’s medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative® to community organizations that are working to combat HIV in the U.S. South. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contacts

Jacquie Ross, CFA, Investors
(650) 358-1054

Hayley Home, Media
(916) 402-2864

Gilead Sciences, Inc.

NASDAQ:GILD

Release Versions

Contacts

Jacquie Ross, CFA, Investors
(650) 358-1054

Hayley Home, Media
(916) 402-2864

More News From Gilead Sciences, Inc.

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation today announced that it has committed over $3 million in grants to expand access to food in communities across the United States. Gilead Foundation Healing Hunger awards will enable 14 regionally focused organizations to meet the unique needs of their communities by improving long-term nutrition access. The funding, distributed through the Gilead Foundation, supports organizations addressing food insecurity in California, North Carolina, N...

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

FOSTER CITY, Calif. & MBABANE, Eswatini--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as pre-exposure prophylaxis (PrEP) to Eswatini and Zambia. The deliveries advance ongoing efforts to accelerate equitable access to long-acting HIV prevention options across sub-Saharan Africa, which is home to approximately two-thirds of all people livin...

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from a multi-tablet regimen to an investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically non-inferior to multi-tablet regimens. Gilead plans to file th...
Back to Newsroom